# Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin)

> **NCT02354222** · PHASE3 · COMPLETED · sponsor: **Tanabe Pharma Corporation** · enrollment: 154 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Canagliflozin
- **DRUG:** Teneligliptin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02354222
- **Lead sponsor:** Tanabe Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2016-02
- **Final completion:** 2016-02
- **Target enrollment:** 154 (ACTUAL)
- **Last updated:** 2026-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02354222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02354222, "Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02354222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*